Iambic 提交第二款自有 AI 发现候选药 IAM217 的 IND
Public reviewed event · Mon Oct 05 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 1 currently public evidence items
Event summary
据 Iambic 官方公告，已提交 IAM217 的 IND 申请。提交申请不等于监管批准，也不代表临床疗效已获证实。
Public evidence and original sources
Iambic Submits IND for a Potentially Brain-Penetrant KIF18A Inhibitor IAM217, Its Second Wholly Owned AI-Discovered Candidate today announced the submission of an Investigational New Drug (IND) application
Iambic official newsroom
- Iambic Therapeutics · AI, models, and data ·